Author/Editor		Hojnik, M
Title		Reaktivnost protiteles iz serumov bolnikov s trombozo in bolnikov brez nje s kardiolipinom in beta2-glikoproteinom I
Type		monografija
Place		Ljubljana
Publisher		Medicinska fakulteta
Publication year		1994
Volume		str. 64
Language		slo
Abstract		Antiphospholid antibodies (aPL) detected by solid phase immunoassays using anionic phospholipids as the antigen or by phospholipid dependent coagulation assays are associated with thrombosis, pregnancy loss and thrombocytopenia. The combination of at least one of these clinical features and increased blood aPL level is termed the antiphospholipid syndrome (APS). In contrast, aPL occurring in infections do not predispose to the APS. Recently, beta2-glycoprotein I (beta2GPl), a plasma apolipoprotein with anticoagulant properties was found to enhance the binding of aPL to anionic phospholipids. This has raised a dilemma about the antigen relevant for antibodies associated with the APS, which may either be phospholipids, beta2GPl or a phospholipid-beta2GPl complex. To assess these alternatives, we studied the influence of beta2GPl on binding of antibodies from various patients to phospholipid cardiolipin, as well as the antibody binding to beta2GPl itself. We included 37 patients in acute phase of idiopathic deep vein thrombosis, 10 patients with the primary APS who had prior thrombosis, and 61 patients with leprosy and no history of thrombosis. Antibodies to cardiolipin (aCL) and antibodies to beta2GPl were measured in serum using enzyme-linked immunosorbent assay technique. The binding specificity of antibodies was evaluated by fluid phase inhibition experiments. In the presence of bovine beta2GPl, aCL were detected in all patients with the primary APS, in 7 (19 percent) patients with idiopathic deep vein thrombosis and in 59 (97 percent) patients with leprosy. In the absence of beta2GPl, cardiolipin binding by the antibodies from patients with thrombosis was either lower or equal to that in the presence of beta2GPl; increased aCL levels were detected in 3 (30 percent) patients with the primary APS and in 2 (5 percent) patients with idiopathic deep vein thrombosis.(trunc.)
Descriptors		THROMBOSIS ANTIPHOSPHOLIPID SYNDROME LEPROSY ANTIBODIES, ANTICARDIOLIPIN GLYCOPROTEINS ANTIBODIES, ANTIPHOSPHOLIPID CARDIOLIPINS